Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD comparison of subcutaneous versus intravenous canakinumab in rheumatoid arthritis
2006-004666-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of canakinumab in rheumatoid arthritis (RA) (2 arms), sponsored by Novartis. Primary endpoints: PK/PD relationship in joint fluid and PK/PD relationship in serum. Started Mar 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2006-004666-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004666-14.